Clinical and genetic aspects of testicular germ cell tumours

Hereditary Cancer in Clinical Practice

Volumn 6, Issue 1, 2008, Pages 3-14

  Lutke Holzik, Martijn F ^a,b   Sijmons, Rolf H ^a   Hoekstra Weebers, Josette E H M ^a,c   Sleijfer, Dirk Th ^a   Hoekstra, Harald J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

^c Integraal Kankercentrum Noord Nederland   (Netherlands)

Author keywords

Familial; Genetics; Review; Testicular germ cell tumour; Therapy

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE;

CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; CRYPTORCHISM; FAMILY HISTORY; GENE MUTATION; GENETIC LINKAGE; GENETIC PREDISPOSITION; GERM CELL TUMOR; HAPLOTYPE; HUMAN; METASTASIS; RADIATION DOSE; REVIEW; SEMINOMA; TWINS; Y CHROMOSOME;

EID: 40949142370     PISSN: 17312302     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Cancer in the Netherlands, trends, prognoses and implications for call of health. www.kwfkankerbestrijding.nl/content/documents/ SCK_rapport_Kanker_in_Nederland.pdf 2004.
2. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Horwich A, Klepp O, Laguna MP, Pizzocaro G. Guidelines on testicular cancer. Eur Urol 2005; 48: 885-894.
3. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, de Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15: 1377-1399.
4. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603.
5. Abouassaly R, Klein EA, Raghavan D. Complications of surgery and chemotherapy for testicular cancer. Uro Oncol 2005; 23: 447-455.
6. Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ, de Vries EG, Willemse PB, Mulder NH, van den Berg MP, Koops HS, Sleijfer DT. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18: 1725-1732.
7. Nuver J, Smit AJ, Wolffenbuttel BH, Sluiter WJ, Hoekstra HJ, Sleijfer DT, Gietema JA. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005; 23: 3718-3725.
8. Nuver J, Smit AJ, Sleijfer DT, van Gessel AI, van Roon AM, van der Meer J, van den Berg MP, Hoekstra HJ, Sluiter WJ, Gietema JA. Left ventricular and cardiac autonomic function in survivors of testicular cancer. Eur J Clin Invet 2005; 35: 99-103.
9. Fleer J. Quality of life of testicular cancer survivors. Thesis: http://irs.ub.rug.nl/ppn/291569412. University of Groningen, The Netherlands 2006.
10. Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G, Skakkebaek NE. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol 2005; 16: 863-868.
11. Oosterhuis JW, Looijenga LH, Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer 2005; 5: 210-222.
12. Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 2001; 16: 972-978.
13. von Eyben FE. Chromosomes, genes, and development of testicular germ cell tumors. Cancer Genet Cytogenet 2004; 151: 93-138.
14. Reuter VE. Origins and molecular biology of testicular germ cell tumors. Mod Pathol 2005; 18 (Suppl 2): S51-S60.
15. Dearnaley D, Huddart R, Horwich A. Regular review: Managing testicular cancer. Br Med J 2001; 322: 1583-1588.
16. Korkola JE, Houldsworth J, Chadalavada RS, Olshen AB, Dobrzynski D, Reuter VE, Bosl GJ, Chaganti RS. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res 2006; 66: 820-827.
17. McIntyre A, Summersgill B, Grygalewicz B, Gillis AJ, Stoop J, van Gurp RJ, Dennis N, Fisher C, Huddart R, Cooper C, Clark J, Oosterhuis JW, Looijenga LH, Shipley J. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res 2005; 65: 8085-8089.
18. Voorhoeve PM, Ie Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, Zlotorynski E, Yabuta N, De Vita G, Nojima H, Looijenga LH, Agami R. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006; 124: 1169-1181.
19. van Basten JP, Schrafford Koops H, Sleijfer DT, Pras E, van Driel MF, Hoekstra HJ. Current concepts about testicular cancer. Eur J Surg Oncol 1997; 23: 354-360.
20. Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Partridge SE, Huddart RA. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med 2000; 27: 590-594.
21. Gels ME, Hoekstra HJ, Sleijfer DT, Marrink J, de Bruijn HW, Molenaar WM, Freling NJ, Droste JH, Schraffordt KH. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 1995; 13: 1188-1194.
22. Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, de Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005; 366: 293-300.
23. de Wit R, Stoter G. Treatment of metastatic testicular carcinoma according to prognosis; new development. Ned Tijdschr Geneeskd 2001; 145: 1194-1199.
24. de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fosså SD, Cook P, de Prijck L, Stenning S, Collette L. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001; 19: 1629-1640.
25. De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F, Lang A, Kletter K, Dohmen BM, Dittrich C, Pont J. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 22: 1034-1039.
26. Lutke Holzik MF, Hoekstra HJ, Mulder NH, Suurmeijer AJ, Sleijfer DT, Gietema JA. Non-germ cell malignancy in residual or recurrent mass after chemotherapy for nonseminomatous testicular germ cell tumor. Ann Surg Oncol 2003; 10: 131-135.
27. Fizazi K, Tjulandin S, Salvioni R, Germa-Lluch JR, Bouzy J, Ragan D, Bokemeyer C, Gerl A, Flechon A, de Bono JS, Stenning S, Horwich A, Pont J, Albers P, De Giorgi U, Bower M, Bulanov A, Pizzocaro G, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy - results from on international study group. J Clin Oncol 2001; 19: 2647-2657.
28. Dieckmann KP, Pichlmeier U. The prevalence of familial testicular cancer: an analysis of two patient populations and a review of the literature. Cancer 1997; 80: 1954-1960.
29. Dong C, Lönnstedt I, Hemminki K. Familial testicular cancer and second primary cancers in testicular cancer patients by histological type. Eur J Cancer 2001; 37: 1878-1885.
30. Forman D, Oliver RT, Brett AR, Marsh SG, Moses JH, Bodmer JG, Chilvers CE, Pike MC. Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. Br J Cancer 1992; 65: 255-262.
31. Heimdal K, Olsson H, Tretli S, Flodgren P, Børresen AL, Fossa SD. Familial testicular cancer in Norway and southern Sweden. Br J Cancer 1996; 73: 964-969.
32. Kruse C. Bilateral and familial occurrence of germ cell tumors of the testis. Urologe A 1987; 26: 61-62.
33. Ondrus D, Kuba D, Chrenova S, Matoska J. Familial testicular cancer and developmental anomalies. Neoplasma 1997; 44: 59-61.
34. Patel SR, Kvols LK, Richardson RL. Familial testicular cancer: report of six cases and review of the literature. Mayo Clin Proc 1990; 65: 804-808.
35. Polednak AP. Familial testicular cancer in a population-based cancer registry. Urol Int 1996; 56: 238-240.
36. Sonneveld DJ, Sleijfer DT, Schraffordt Koops H, Sijmons RH, van der Graaf WT, Sluiter WJ, Hoekstra HJ. Familial testicular cancer in a single-centre population. Eur J Cancer 1999; 35: 1368-1373.
37. Tollerud DJ, Blattner WA, Fraser MC, Brown LM, Pottern L, Shapiro E, Kirkemo A, Shawker TH, Javadpour N, O'Connell K, et al. Familial testicular cancer and urogenital developmental anomalies. Cancer 1985; 55: 1849-1854.
38. Westergaard T, Olsen JH, Frisch M, Kroman N, Nielsen JW, Melbye M. Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population-based study. Int J Cancer 1996; 66: 627-631.
39. Goss PE, Bulbul MA. Familial testicular cancer in five members of a cancer-prone kindred. Cancer 1990; 66: 2044-2046.
40. Forman D, Gallagher R, Møller H, Swerdlow TJ. Aetiology and epidemiology of testicular cancer: report of consensus group. Prog Clin Biol Res 1990; 357: 245-253.
41. Sonneveld DJ, Schaapveld M, Sleijfer DT, te Meerman GJ, van der Graaf WT, Sijmons RH, Schraffordt Koops H, Hoekstra HJ. Geographic clustering of testicular cancer incidence in the northern part of The Netherlands. Br J Cancer 1999; 81: 1262-1267.
42. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997; 337: 242-253.
43. Heimdal K, Fosså SD. Genetic factors in malignant germ-cell tumors. World J Urol 1994; 12: 178-181.
44. Senturia YD. The epidemiology of testicular cancer. Br J Urol 1987; 60: 285-291.
45. Looijenga LH, de Leeuw H, van Oorschot M, van Gurp RJ, Stoop H, Gillis AJ, de Gouveia Brazao CA, Weber RF, Kirkels WJ, van Dijk T, von Lindern M, Valk P, Lajos G, Olah E, Nesland JM, Fosså SD, Oosterhuis JW. Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res 2003; 63: 7674-7678.
46. Rapley EA, Hockley S, Warren W, Johnson L, Huddart R, Crockford G, Forman D, Leahy MG, Oliver DT, Tucker K, Friedlander M, Phillips KA, Hogg D, Jewett MA, Lohynska R, Daugaard G, Richard S, Heidenreich A, Geczi L, Bodrogi I, Olah E, Ormiston WJ, Daly PA, Looijenga LH, Guilford P, Aass N, Fosså SD, Heimdal K, Tjulandin SA, Liubchenko L, Stoll H, Weber W, inhorn L, Weber BL, McMaster M, Greene MH, Bishop DT, Easton D, Stratton MR. Somatic mutations of KIT in familial testicular germ cell tumours. Br J Cancer 2004; 90: 2397-2401.
47. Aetiology of testicular cancer: association with congenital abnormalities, age at puberty, infertility, and exercise. United Kingdom Testicular Cancer Study Group. BMJ 1994; 308: 1393-1399.
48. Gallagher RP, Huchcroft S, Phillips N, Hill GB, Coldman AJ, Coppin C, Lee T. Physical activity, medical history, and risk of testicular cancer (Alberta and British Columbia, Canada). Cancer Causes Control 1995; 6: 398-406.
49. Harland SJ, Cook PA, Fossa SD, Horwich A, Mead GM, Parkinson MC, Roberts JT, Stenning SP. Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J Urol 1998; 160: 1353-1357.
50. Jacobsen R, Bostofte E, Engholm G, Hansen J, Olsen JH, Skakkebaek NE, Moller H. Risk of testicular cancer in men with abnormal semen characteristics: cohort study. BMJ 2000; 321: 789-792.
51. Kent-First M, Muallem A, Shultz J, Pryor J, Roberts K, Nolten W, Meisner L, Chandley A, Gouchy G, Jorgensen L, Havighurst T, Grosch J. Defining regions of the Y-chromosome responsible for male infertility and identification of a fourth AZF region (AZFd) by Y-chromosome microdeletion detection. Mol Reprod Dev 1999; 53: 27-41.
52. Layman LC. Human gene mutations causing infertility. J Med Genet 2002; 39: 153-161.
53. Vogt PH, Edelmann A, Kirsch S, Henegariu O, Hirschmann P, Kiesewetter F, Köhn FM, Schill WB, Farah S, Ramos C, Hartmann M, Hartschuh W, Meschede D, Behre HM, Castel A, Nieschlag E, Weidner W, Gröne HJ, Jung A, Engel W, Haidl G. Human Y chromosome azoospermia factors (AZF) mapped to different subregions in Yq11. Hum Mol Genet 1996; 5: 933-943.
54. Foresta C, Moro E, Garolla A, Onisto M, Ferlin A. Y chromosome microdeletions in cryptorchidism and idiopathic infertility. J Clin Endocrinol Metab 1999; 84: 3660-3665.
55. Lutke Holzik MF, Storm K, Sijmons RH, D'hollander M, Arts EG, Verstraaten ML, Sleijfer DT, Hoekstra HJ. Absence of constitutional Y chromosome AZF deletions in patients with testicular germ cell tumors. Urology 2005; 65: 196-201.
56. Repping S, Skaletsky H, Brown L, van Daalen SK, Korver CM, Pyntikova T, Kuroda-Kawaguchi T, de Vries JW, Oates RD, Silber S, van der Veen F, Page DC, Rozen S. Polymorphism for a 1.6-Mb deletion of the human Y chromosome persists through balance between recurrent mutation and haploid selection. Nat Genet 2003; 35: 247-251.
57. Nathanson KL, Kanetsky PA, Hawes R, Vaughn DJ, Letrero R, Tucker K, Friedlander M, Phillips KA, Hogg D, Jewett MA, Lohynska R, Daugaard G, Richard S, Chompret A, Bonaiti-Pellie C, Heidenreich A, Olah E, Geczi L et al. The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet 2005; 77: 1034-1043.
58. Heimdal K, Olsson H, Tretli S, Flodgren P, Børresen AL, Fossa SD. Risk of cancer in relatives of testicular cancer patients. Br J Cancer 1996; 73: 970-973.
59. Nichols CR, Heerema NA, Palmer C, Loehrer PJ Sr, Williams SD, Einhorn LH. Klinefelter's syndrome associated with mediastinal germ cell neoplasms. J Clin Oncol 1987; 5: 1290-1294.
60. Fosså SD, Aass N, Heilo A, Daugaard G, E Skakkebaek N, Stenwig AE, Nesland JM, Looijenga LH, Oosterhuis JW. Testicular carcinoma in situ in patients with extragonadal germ-cell tumours: the clinical role of pretreatment biopsy. Ann Oncol 2003; 14: 1412-1418.
61. Levin HS. Tumors of the testis in intersex syndromes. Urol Clin North Am 2000; 27: 543-551.
62. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000; 355: 165-169.
63. Satgé D, Sasco AJ, Curé H, Leduc B, Sommelet D, Vekemans MJ. An excess of testicular germ cell tumors in Down's syndrome: three case reports and a review of the literature. Cancer 1997; 80: 929-935.
64. Lutke Holzik MF, Sijmons RH, Sleijfer DT, Sonneveld DJ, Hoekstra-Weebers JE, van Echten-Arends J, Hoekstra HJ. Syndromic aspects of testicular carcinoma. Cancer 2003; 97: 984-992.
65. Swerdlow AJ, De Stavola BL, Swanwick MA, Maconochie NE. Risks of breast and testicular cancers in young adult twins in England and Wales: evidence on prenatal and genetic aetiology. Lancet 1997; 350: 1723-1728.
66. Sharpe RM. The Oestrogen hypothesis' - where do we stand now? Int J Androl 2003; 26: 2-15.
67. Braun MM, Caporaso NE, Page WF, Hoover RN. Prevalence of a history of testicular cancer in a cohort of elderly twins. Acta Genet Med Gemellol (Roma) 1995; 44: 189-192.
68. Dieckmann KP, Endsin G, Pichlmeier U. How valid is the prenatal estrogen excess hypothesis of testicular germ cell cancer? A case control study on hormone-related factors. Eur Urol 2001; 40: 677-683.
69. Nicholson PW, Harland SJ. Inheritance and testicular cancer. Br J Cancer 1995; 71: 421-426.
70. Heimdal K, Olsson H, Tretli S, Fosså SD, Børresen AL, Bishop DT. A segregation analysis of testicular cancer based on Norwegian and Swedish families. Br J Cancer 1997; 75: 1084-1087.
71. Møller H. Trends in sex-ratio, testicular cancer and male reproductive hazards: are they connected? APMIS 1998; 106: 232-238.
72. Petersen PM, Skakkebaek NE, Giwercman A. Gonadal function in men with testicular cancer: biological and clinical aspects. APMIS 1998; 106: 24-34.
73. Sonneveld DJ, Hoekstra HJ, van der Graaf WT, Sluiter WJ, Mulder NH, Willemse PH, Koops HS, Sleijfer DT. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 2001; 91: 1304-1315.
74. Sonneveld DJ, Lutke Holzik MF, Nolte IM, Sleijfer DT, van der Graaf WT, Bruinenberg M, Sijmons RH, Hoekstra HJ, Te Meerman GJ. Testicular carcinoma and HLA Class II genes. Cancer 2002; 95: 1857-1863.
75. Özdemir E, Kakehi Y, Mishina M, Ogawa O, Okada Y, Özdemir D, Yoshida O. High-resolution HLA-DRB1 and DQB1 genotyping in Japanese patients with testicular germ cell carcinoma. Br J Cancer 1997; 76: 1348-1352.
76. Rapley EA, Crockford GP, Teare D, Biggs P, Seal S, Barfoot R, Edwards S, Hamoudi R, Heimdal K, Fossâ SD, Tucker K, Donald J, Collins F, Friedlander M, Hogg D, Goss P, Heidenreich A, Ormiston W, Daly PA, Forman D, Oliver TD, Leahy M, Huddart R, Cooper CS, Bodmer JG, Easton DF, Stratton MR, Bishop DT. Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet 2000; 24: 197-200.
77. Rapley EA, Crockford GP, Easton D, Stratton MR, Bishop DT; International Testicular Cancer Linkage Consortium. Localisation of susceptibility genes for familial testicular germ cell tumour. APMIS 2003; 111: 128-135.
78. Lutke Holzik MF, Hoekstra HJ, Sijmons RH, Sonneveld DJ, van der Steege G, Sleijfer DT, Nolte IM. Re-analysis of the Xq27-Xq28 region suggests a weak association of an X-linked gene with sporadic testicular germ cell tumour without cryptorchidism. Eur J Cancer 2006; 42: 1869-1874.
79. Austoker J. Screening for ovarian, prostatic, and testicular cancers. BMJ 1994; 309: 315-320.
80. Moiseyenko VM, Danilov AO, Baldueva IA, Danilova AB, Tyukavina NV, Larin SS, Kiselev SL, Orlova RV, Anisimov VV, Semenova AI, Shchekina LA, Gafton GI, Kochnev VA, Barchuk AS, Kanaev SV, Hanson KP, Georgiev GP. Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors: miscellaneous tumors. Ann Oncol 2005; 16: 162-168.
81. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 273: 1516-1517.
82. Youngren KK, Nadeau JH, Matin A. Testicular cancer susceptibility in the 129.MOLF-Chr19 mouse strain: additive effects, gene interactions and epigenetic modifications. Hum Mol Genet 2003; 12: 389-398